AYTU BIOPHARMA, INC Payments for (Proceeds from) Other Investing Activities
AYTU BIOPHARMA, INC (AYTU) reported Payments for (Proceeds from) Other Investing Activities of $0 for the 9-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromOtherInvestingActivities · last filed 2025-05-14
- AYTU BIOPHARMA, INC payments for (proceeds from) other investing activities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC payments for (proceeds from) other investing activities for the quarter ending 2024-06-30 was $34.00K, a 78.06% decline year-over-year.
- AYTU BIOPHARMA, INC payments for (proceeds from) other investing activities for the quarter ending 2024-03-31 was $45.00K, a 1025.00% increase year-over-year.
- AYTU BIOPHARMA, INC payments for (proceeds from) other investing activities for the quarter ending 2023-12-31 was $174.00K.
- AYTU BIOPHARMA, INC payments for (proceeds from) other investing activities for fiscal 2024 was $329.00K, a 181.20% increase from fiscal 2023.
- AYTU BIOPHARMA, INC payments for (proceeds from) other investing activities for fiscal 2023 was $117.00K, a 67.14% increase from fiscal 2022.
- AYTU BIOPHARMA, INC payments for (proceeds from) other investing activities for fiscal 2022 was $70.00K.
- AYTU BIOPHARMA, INC payments for (proceeds from) other investing activities for fiscal 2021 was -$40.00K.
| Period end | Payments for (Proceeds from) Other Investing Activities 3 month | Payments for (Proceeds from) Other Investing Activities 6 month | Payments for (Proceeds from) Other Investing Activities 9 month | Payments for (Proceeds from) Other Investing Activities 12 month | Payments for (Proceeds from) Other Investing Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | $0.00 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $0.00 10-Q · filed 2025-02-12 | ||||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $79.00K derived: sum of 2 quarters · filed 2025-05-14 | $253.00K derived: sum of 3 quarters · filed 2025-05-14 | $329.00K 10-K · filed 2024-09-26 | |
| 2024-03-31 | $45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | $219.00K derived: sum of 2 quarters · filed 2025-05-14 | $295.00K 10-Q · filed 2025-05-14 | $450.00K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $250.00K 10-Q · filed 2025-02-12 | $405.00K derived: sum of 3 quarters · filed 2025-02-12 | $409.00K derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-09-30 | $76.00K 10-Q · filed 2023-11-14 | $231.00K derived: sum of 2 quarters · filed 2024-09-26 | $76.00K 10-Q · filed 2024-11-13 | $235.00K derived: sum of 4 quarters · filed 2024-09-26 | |
| 2023-06-30 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $159.00K derived: sum of 2 quarters · filed 2024-09-26 | $159.00K derived: sum of 3 quarters · filed 2024-09-26 | $117.00K 10-K · filed 2024-09-26 | $112.00K 10-K · filed 2023-10-12 |
| 2023-03-31 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $4.00K derived: sum of 2 quarters · filed 2024-05-15 | -$38.00K 10-Q · filed 2024-05-15 | -$37.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | -$42.00K 10-Q · filed 2024-02-14 | -$41.00K derived: sum of 3 quarters · filed 2024-02-14 | $0.00 derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-09-30 | -$42.00K 10-Q · filed 2023-11-14 | -$41.00K derived: sum of 2 quarters · filed 2023-11-14 | $0.00 derived: sum of 3 quarters · filed 2023-11-14 | -$8.00K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $42.00K derived: sum of 2 quarters · filed 2023-10-12 | $34.00K derived: sum of 3 quarters · filed 2023-10-12 | $70.00K 10-K · filed 2023-10-12 | |
| 2022-03-31 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | $33.00K derived: sum of 2 quarters · filed 2023-05-11 | $69.00K 10-Q · filed 2023-05-11 | $33.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$8.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21 | $28.00K 10-Q · filed 2023-02-21 | -$8.00K derived: sum of 3 quarters · filed 2023-02-21 | -$8.00K derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-09-30 | $36.00K 10-Q/A · filed 2023-02-21 | $0.00 derived: sum of 2 quarters · filed 2023-02-21 | $0.00 derived: sum of 3 quarters · filed 2023-02-21 | $6.00K derived: sum of 4 quarters · filed 2023-02-21 | |
| 2021-06-30 | -$36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | -$36.00K derived: sum of 2 quarters · filed 2022-09-27 | -$30.00K derived: sum of 3 quarters · filed 2022-09-27 | -$40.00K 10-K · filed 2022-09-27 | |
| 2021-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | $6.00K derived: sum of 2 quarters · filed 2022-05-16 | -$4.00K 10-Q · filed 2022-05-16 | ||
| 2020-12-31 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | -$4.00K 10-Q · filed 2022-02-14 | |||
| 2020-09-30 | -$10.00K 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | -$6.00K 10-K · filed 2021-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |